recombinant human fap (MedChemExpress)
Structured Review
Recombinant Human Fap, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+fap/FAP%2C+Human/pm41325906-174-0-7
Average 93 stars, based on 1 article reviews
Images
Related Articles
Recombinant:Article Title: Structure-guided design and clinical evaluation of 68 Ga-GP01 for FAP-targeted PET imaging in solid tumors. Article Snippet: Fibroblast activation protein (FAP)-targeted radioligands have shown superior performance in detecting FAPexpressing cancers.. However, the quinoline-based agent 68Ga-FAPI-46 exhibits only moderate in vivo stability and suboptimal pharmacokinetics.. To overcome these limitations, a FAP inhibitor, GP01 was designed by introducing N-methyl-benzenesulfonic acid side chain on FAPI-46 with enhanced binding affinity and improved in vivo stability. Concentration Assay:Article Title: Structure-guided design and clinical evaluation of 68 Ga-GP01 for FAP-targeted PET imaging in solid tumors. Article Snippet: Fibroblast activation protein (FAP)-targeted radioligands have shown superior performance in detecting FAPexpressing cancers.. However, the quinoline-based agent 68Ga-FAPI-46 exhibits only moderate in vivo stability and suboptimal pharmacokinetics.. To overcome these limitations, a FAP inhibitor, GP01 was designed by introducing N-methyl-benzenesulfonic acid side chain on FAPI-46 with enhanced binding affinity and improved in vivo stability. Incubation:Article Title: Structure-guided design and clinical evaluation of 68 Ga-GP01 for FAP-targeted PET imaging in solid tumors. Article Snippet: Fibroblast activation protein (FAP)-targeted radioligands have shown superior performance in detecting FAPexpressing cancers.. However, the quinoline-based agent 68Ga-FAPI-46 exhibits only moderate in vivo stability and suboptimal pharmacokinetics.. To overcome these limitations, a FAP inhibitor, GP01 was designed by introducing N-methyl-benzenesulfonic acid side chain on FAPI-46 with enhanced binding affinity and improved in vivo stability. |

